The utility of a novel triple marker (combination of TTF1, napsin A, and p40) in the subclassification of non-small cell lung cancer

Human Pathology

Volumn 45, Issue 5, 2014, Pages 926-934

  Ao, Ming Hui ^a   Zhang, Hui ^a   Sakowski, Lynne ^a   Sharma, Rajni ^a   Illei, Peter B ^a   Gabrielson, Edward ^a   Askin, Frederic ^a   Li, Qing Kay ^a  

^a JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

Immunohistochemical markers; Napsin A; Non small cell lung carcinoma (NSCLC); Novel triple stain marker; P40

Indexed keywords

IMMUNOHISTOCHEMICAL MARKERS; NAPSIN A; NON-SMALL CELL LUNG CARCINOMA (NSCLC); NOVEL TRIPLE STAIN MARKER; P40;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ASPARTIC ACID ENDOPEPTIDASES; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNODOMINANT EPITOPES; LUNG NEOPLASMS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; SENSITIVITY AND SPECIFICITY;

EID: 84898826641     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2014.01.005     Document Type: Article

References (33)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2012 CA Cancer J Clin 62 2012 10 29
2. W.D. Travis, E. Brambilla, and M. Noguchi et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma J Thorac Oncol 6 2011 244 285
3. F.R. Hirsch, A. Spreafico, S. Novello, M.D. Wood, L. Simms, and M. Papotti The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review J Thorac Oncol 3 2008 1468 1481
4. F. Janku, I. Garrido-Laguna, L.B. Petruzelka, D.J. Stewart, and R. Kurzrock Novel therapeutic targets in non-small cell lung cancer J Thorac Oncol 6 2011 1601 1612 [Review]
5. D. Munfus-McCray, M. Cui, Z. Zhang, F. Askin, E. Gabrielson, and Q.K. Li Comparison of EGFR and KRAS mutations in primary and unpaired metastatic lung adenocarcinoma with potential chemotherapy effect Hum Pathol 42 2011 1447 1453
6. Q.K. Li, A. Singh, S. Biswal, F. Askin, and E. Gabrielson KEAP1 gene mutations and NRF2 activation are common in pulmonary papillary adenocarcinoma J Hum Genet 56 2011 230 234
7. Q.K. Li, E. Gabrielson, and H. Zhang Application of glycoproteomics in the discovery of biomarkers for lung cancer Proteomics: Clinical App. 5-6 2012 244 256
8. T. Kosaka, Y. Yatabe, H. Endoh, H. Kuwano, T. Takahashi, and T. Mitsudomi Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications Cancer Res 64 2004 8919 8923
9. J.G. Paez, P.A. Jänne, and J.C. Lee et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
10. M.-S. Tsao, A. Sakurada, and J.C. Cutz et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome N Engl J Med 353 2005 133 144
11. T. Mitsudomi, and Y. Yatabe Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer Cancer Sci 98 2007 1817 1824
12. M. Soda, Y.L. Choi, and M. Enomoto et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer Nature 448 2007 561 566
13. W. Sterlacci, S. Savic, and T. Schmid et al. Tissue-sparing application of the newly proposed IASLC/ATS/ERS classification of adenocarcinoma of the lung shows practical diagnostic and prognostic impact Am J Clin Pathol 137 2012 946 956
14. R.C.W. Yung, S. Otell, and P. Illei et al. Improvement of cellularity on cell block preparations using the so-called tissue coagulum clot method during endobronchial ultrasound-guided transbronchial fine-needle aspiration Cancer Cytopathol 120 2012 185 195
15. D. Feller-Kopman, R.C.W. Yung, F. Burroughs, and Q.K. Li Cytology of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA). A study of 135 cases with histology correlation Cancer Cytopathol 117 2009 482 490
16. L.M. Stoll, M.W. Johnson, E. Gabrielson, F. Askin, D.P. Clark, and Q.K. Li The utility of Napsin A in the identification of primary and metastatic lung adenocarcinoma among cytologically "poorly differentiated carcinoma" Cancer Cytopathol 118 2010 441 449
17. B.Z. Ring, R.S. Seitz, and R.A. Beck et al. A novel five-antibody immunohistochemical test for subclassification of lung carcinoma Mod Pathol 22 2009 1032 1043
18. S. Mukhopadhyay, and A.L. Katzenstein Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF1, napsin A, p63, and CK5/6 Am J Surg Pathol 35 2011 15 25
19. N. Rekhtman, D.C. Ang, C.S. Sima, W.D. Travis, and A.L. Moreira Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens Mod Pathol 24 2011 1348 1359
20. D. Tacha, C. Yu, R. Bremer, W. Qi, and T. Haas A 6-antibody panel for the classification of lung adenocarcinoma versus squamous cell carcinoma Appl Immunohistochem Mol Morphol 20 2012 201 207
21. J.A. Bishop, J. Teruya-Feldstein, W.H. Westra, G. Pelosi, W.D. Travis, and N. Rekhtman p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma Mod Pathol 25 2012 405 415
22. A.R. Nobre, A. Albergaria, and F. Schmitt p40: a p63 isoform useful for lung cancer diagnosis. A review of the physiological and pathological role of p63 Acta Cytol 57 2012 1 8
23. D. Nonaka A study of ΔNp63 expression in lung non-small cell carcinomas Am J Surg Pathol 36 6 2012 895 899
24. K. Whithaus, J. Fukuoka, T.J. Prihoda, and J. Jagirdar Evaluation of napsin A, cytokeratin 5/6, p63, and thyroid transcription factor 1 in adenocarcinoma versus squamous cell carcinoma of the lung Arch Pathol Lab Med 136 2012 155 162
25. N. Fatima, C. Cohen, D. Lawson, and M.T. Siddiqui TTF1 and Napsin A double stain: a useful marker for diagnosing lung adenocarcinoma on fine-needle aspiration cell blocks Cancer Cytopathol 119 2011 127 133
26. H. Johnson, C. Cohen, N. Fatima, D. Duncan, and M.T. Siddiqui Thyroid transcription factor 1 and napsin a double stain: utilizing different vendor antibodies for diagnosing lung adenocarcinoma Acta Cytol 56 2012 596 602
27. S. Sethi, L. Geng, and V.B. Shidham et al. Dual color multiplex TTF1 + napsin A and p63 + CK5 immunostaining for subcategorizing of poorly differentiated pulmonary non-small carcinomas into adenocarcinoma and squamous cell carcinoma in fine needle aspiration specimens Cytojournal. 9 2012 10
28. A.F. Brown, D. Sirohi, and J. Fukuoka et al. Tissue-preserving antibody cocktails to differentiate primary squamous cell carcinoma, adenocarcinoma, and small cell carcinoma of lung Arch Pathol Lab Med 137 2013 1274 1281
29. S.B. Edge, D.R. Byrd, C.C. Compton, A.G. Fritz, F.L. Greene, and A. Trotti AJCC Cancer Staging Manual 7th ed 2010 Springer New York
30. Y. Sakai, T. Nakai, and C. Ohbayashi et al. Immunohistochemical profiling of ALK fusion gene-positive adenocarcinomas of the lung Int J Surg Pathol 21 2013 476 482
31. D.A. Eberhard, B.E. Johnson, and L.C. Amler et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib J Clin Oncol 23 2005 5900 5909
32. W. Pao, T.Y. Wang, and G.J. Riely et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib PLoSMed 2 2005 e17
33. H. Linardou, I.J. Dahabreh, and D. Kanaloupiti et al. Assessment of somatic KRAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small cell lung cancer and metastatic colorectal cancer Lancet Oncol 9 2008 962 972